IS8483A - Heterósýklísk virk efni gegn mígreni - Google Patents
Heterósýklísk virk efni gegn mígreniInfo
- Publication number
- IS8483A IS8483A IS8483A IS8483A IS8483A IS 8483 A IS8483 A IS 8483A IS 8483 A IS8483 A IS 8483A IS 8483 A IS8483 A IS 8483A IS 8483 A IS8483 A IS 8483A
- Authority
- IS
- Iceland
- Prior art keywords
- migraine
- active agents
- heterocyclic active
- heterocyclic
- agents
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52743803P | 2003-12-05 | 2003-12-05 | |
| US11/004,706 US7569578B2 (en) | 2003-12-05 | 2004-12-03 | Heterocyclic anti-migraine agents |
| PCT/US2004/040721 WO2005056550A2 (en) | 2003-12-05 | 2004-12-06 | Heterocyclic anti-migraine agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8483A true IS8483A (is) | 2006-05-26 |
Family
ID=34680800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8483A IS8483A (is) | 2003-12-05 | 2006-05-26 | Heterósýklísk virk efni gegn mígreni |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7569578B2 (is) |
| EP (1) | EP1689738A2 (is) |
| JP (1) | JP2007516967A (is) |
| KR (1) | KR20070026339A (is) |
| AR (1) | AR046787A1 (is) |
| AU (1) | AU2004297230A1 (is) |
| BR (1) | BRPI0417337A (is) |
| CA (1) | CA2549401A1 (is) |
| CO (1) | CO5690595A2 (is) |
| IL (1) | IL176043A0 (is) |
| IS (1) | IS8483A (is) |
| MX (1) | MXPA06005970A (is) |
| NO (1) | NO20062489L (is) |
| PE (1) | PE20050670A1 (is) |
| RU (1) | RU2006124026A (is) |
| TW (1) | TW200524601A (is) |
| WO (1) | WO2005056550A2 (is) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842808B2 (en) * | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| ES2616539T3 (es) * | 2002-06-05 | 2017-06-13 | Bristol-Myers Squibb Company | Antagonistas de receptores de péptidos relacionados con el gen de calcitonina |
| US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| WO2005058823A1 (ja) * | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) * | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| EP2094692B1 (en) | 2006-11-01 | 2012-11-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| JP2010508358A (ja) * | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用 |
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| WO2009149837A1 (en) | 2008-06-09 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof |
| DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
| DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| CA2752603C (en) | 2009-02-18 | 2016-04-05 | Bayer Pharma Aktiengesellschaft | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof |
| EP2451817B1 (en) | 2009-07-10 | 2013-09-04 | Bayer Intellectual Property GmbH | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| CA2877526A1 (en) | 2012-06-20 | 2013-12-27 | Novartis Ag | Complement pathway modulators and uses thereof |
| WO2014062548A1 (en) | 2012-10-18 | 2014-04-24 | Bristol-Myers Squibb Company | Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists |
| NZ716598A (en) | 2012-11-20 | 2017-02-24 | Merial Inc | Anthelmintic compounds and compositions and method of using thereof |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| KR102894264B1 (ko) * | 2015-03-10 | 2025-12-02 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| TWI728953B (zh) | 2015-04-24 | 2021-06-01 | 美商安美基公司 | 治療或預防偏頭痛之方法 |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| AU2018348350B2 (en) | 2017-10-11 | 2024-05-02 | Aurigene Oncology Limited | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| MX2020004531A (es) | 2017-11-03 | 2020-08-03 | Aurigene Discovery Tech Ltd | Inhibidores dobles de tim-3 y las vias de pd-1. |
| EP3706798A1 (en) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
| JP7339262B2 (ja) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Ｐａｃ１抗体及びその使用 |
| WO2022172829A1 (ja) * | 2021-02-15 | 2022-08-18 | 株式会社カネカ | 光学活性インダゾリルアラニン又はインダゾリルアルデヒドの製造方法 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0851759A4 (en) | 1995-09-05 | 2000-12-06 | Smithkline Beecham Corp | COMPOUNDS AND RELATED METHODS |
| EP0934068A1 (en) | 1996-09-09 | 1999-08-11 | Smithkline Beecham Corporation | Compounds and methods |
| DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1998056779A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists |
| US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| US6329389B1 (en) | 1998-04-08 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and use |
| JP2002525371A (ja) | 1998-09-30 | 2002-08-13 | メルク シャープ エンド ドーム リミテッド | Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン |
| DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
| US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
| AU7556800A (en) | 1999-10-07 | 2001-05-10 | Tadeka Chemical Industries, Ltd. | Amine derivatives |
| DE19952147A1 (de) | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19963868A1 (de) | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US7566734B2 (en) | 2000-08-01 | 2009-07-28 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Imidazolyl derivatives |
| US20030181462A1 (en) | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
| DE60234944D1 (de) | 2001-09-27 | 2010-02-11 | Merck & Co Inc | Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren |
| DE10206770A1 (de) | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
| US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
| US20040014679A1 (en) | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
| DE10211770A1 (de) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US7026312B2 (en) | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| ES2616539T3 (es) | 2002-06-05 | 2017-06-13 | Bristol-Myers Squibb Company | Antagonistas de receptores de péptidos relacionados con el gen de calcitonina |
| US20040076587A1 (en) | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
| DE10250080A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10300973A1 (de) | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| EP1606264B1 (en) | 2003-03-14 | 2012-05-02 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirohydantoin cgrp receptor antagonists |
| US7288559B2 (en) | 2003-03-14 | 2007-10-30 | Merck + Co, Inc. | Carboxamide spirohydantoin CGRP receptor antagonists |
| JP4673294B2 (ja) | 2003-03-14 | 2011-04-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質 |
| AU2004222328B2 (en) | 2003-03-14 | 2009-10-08 | Merck Sharp & Dohme Corp. | Aryl spirohydantoin CGRP receptor antagonists |
| EP1606286B1 (en) | 2003-03-14 | 2011-05-11 | Merck Sharp & Dohme Corp. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| US20040248816A1 (en) | 2003-04-01 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Treatment of migraine |
| WO2004091514A2 (en) | 2003-04-15 | 2004-10-28 | Merck & Co., Inc. | Cgrp receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| EP1641781B1 (en) | 2003-06-26 | 2013-03-06 | Merck Sharp & Dohme Corp. | Benzodiazepine CGRP receptor antagonists |
| US7476665B2 (en) | 2003-06-26 | 2009-01-13 | Merck & Co., Inc. | Benzodiazepine CGRP receptor antagonists |
| US20050032783A1 (en) | 2003-07-07 | 2005-02-10 | Boehringer Ingelheim International Gmbh | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| EP1646611A1 (en) | 2003-07-15 | 2006-04-19 | Merck & Co., Inc. | Hydroxypyridine cgrp receptor antagonists |
| US20050065094A1 (en) | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| JP2007524568A (ja) | 2003-12-05 | 2007-08-30 | ブリストル−マイヤーズ スクイブ カンパニー | カルシトニン遺伝子関連ペプチドレセプターアンタゴニスト |
| CN101124217A (zh) | 2004-01-29 | 2008-02-13 | 默克公司 | Cgrp受体拮抗剂 |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102004018796A1 (de) | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018794A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050233980A1 (en) | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
| WO2005102322A1 (de) | 2004-04-20 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102004027912A1 (de) | 2004-06-09 | 2005-12-29 | Grünenthal GmbH | Substituierte Cyclopenten-Verbindungen |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
-
2004
- 2004-12-03 TW TW093137539A patent/TW200524601A/zh unknown
- 2004-12-03 AR ARP040104529A patent/AR046787A1/es unknown
- 2004-12-03 US US11/004,706 patent/US7569578B2/en active Active
- 2004-12-06 PE PE2004001195A patent/PE20050670A1/es not_active Application Discontinuation
- 2004-12-06 BR BRPI0417337-6A patent/BRPI0417337A/pt not_active IP Right Cessation
- 2004-12-06 WO PCT/US2004/040721 patent/WO2005056550A2/en not_active Ceased
- 2004-12-06 AU AU2004297230A patent/AU2004297230A1/en not_active Abandoned
- 2004-12-06 EP EP04813096A patent/EP1689738A2/en not_active Withdrawn
- 2004-12-06 CA CA002549401A patent/CA2549401A1/en not_active Abandoned
- 2004-12-06 JP JP2006542841A patent/JP2007516967A/ja not_active Withdrawn
- 2004-12-06 MX MXPA06005970A patent/MXPA06005970A/es not_active Application Discontinuation
- 2004-12-06 RU RU2006124026/04A patent/RU2006124026A/ru not_active Application Discontinuation
- 2004-12-06 KR KR1020067010916A patent/KR20070026339A/ko not_active Withdrawn
-
2006
- 2006-05-26 IS IS8483A patent/IS8483A/is unknown
- 2006-05-31 NO NO20062489A patent/NO20062489L/no not_active Application Discontinuation
- 2006-05-31 IL IL176043A patent/IL176043A0/en unknown
- 2006-06-01 CO CO06052775A patent/CO5690595A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004297230A1 (en) | 2005-06-23 |
| CO5690595A2 (es) | 2006-10-31 |
| IL176043A0 (en) | 2006-10-05 |
| BRPI0417337A (pt) | 2007-04-17 |
| US7569578B2 (en) | 2009-08-04 |
| WO2005056550A2 (en) | 2005-06-23 |
| JP2007516967A (ja) | 2007-06-28 |
| CA2549401A1 (en) | 2005-06-23 |
| KR20070026339A (ko) | 2007-03-08 |
| WO2005056550A3 (en) | 2005-07-14 |
| EP1689738A2 (en) | 2006-08-16 |
| TW200524601A (en) | 2005-08-01 |
| PE20050670A1 (es) | 2005-09-25 |
| RU2006124026A (ru) | 2008-01-27 |
| AR046787A1 (es) | 2005-12-21 |
| NO20062489L (no) | 2006-06-14 |
| MXPA06005970A (es) | 2006-07-06 |
| US20050153959A1 (en) | 2005-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2016042I2 (el) | Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων | |
| NL1027811A1 (nl) | Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1. | |
| DE50309032D1 (de) | Fungizide wirkstoffkombinationen | |
| ATE461191T1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
| DK2039685T3 (da) | Heterobicycliske forbindelser som P38-inhibitorer | |
| ATE392813T1 (de) | Fungizide wirkstoffkombination | |
| IS7667A (is) | Nýjar bensimídazólafleiður | |
| IS7599A (is) | Heterósýklískir kínasatálmar | |
| IS8320A (is) | N-staðgengnir pýrasólýl-amidýl-bensimidasólýl | |
| DK1663232T3 (da) | Benzimidazolderivater som human chymase-inhibitorer | |
| DK1648867T3 (da) | Ppar-aktive forbindelser | |
| ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
| DE602004012154D1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren | |
| DK1558585T3 (da) | Neurologisk aktive forbindelser | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
| ATE386518T1 (de) | Benzimidazolderivate | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| DE602004032551D1 (de) | Hren dafür | |
| DE602004018746D1 (de) | Hren dafür | |
| ATE538787T1 (de) | Benzimidazol-derivative als raf-kinase-hemmer | |
| ATE402700T1 (de) | Glycinamid-derivate als raf-kinase-hemmer | |
| NO20070299L (no) | Novel heterocyclic compounds | |
| DE502004005409D1 (de) | Sprühfeuchtwerk | |
| ATE308325T1 (de) | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren |